Amir Yousif

Amir Yousif

Auto-generated profile, based on publicly available information

Amir Yousif

Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, Ohio

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
YCYu-Lin Chen
Yu-Lin Chen
AYAmir Yousif
Amir Yousif
CCChung-Hsing Chen
Chung-Hsing Chen
ALAva Lowin
Ava Lowin
ASAbbey A. Saadey
Abbey A. Saadey
HGHazem E. Ghoneim
Hazem E. Ghoneim
Immunotherapy has emerged as a promising treatment for head and neck squamous cell carcinoma, yet clinical responses remain limited. Elevated expression of interferon-stimulated gene 15 (ISG15), commonly observed in oral squamous cell carcinoma (OSCC), may contribute to this limited efficacy. Although chronic interferon signaling is known to impair CD8+ T-cell function, the specific role of secreted ISG15 in T-cell exhaustion remains unclear. In this study, we report that the analysis of human OSCC datasets revealed significant enrichment of the ISG core score, including ISG15, in tumors compared with adjacent nontumor tissues. Using an in vitro model of human T-cell dysfunction, we found that acute ISG15 exposure enhanced CD8+ T-cell effector functions, whereas prolonged exposure induced severe dysfunction via a CD11a/LFA-1–independent, endocytosis-dependent mechanism. In an immunocompetent orthotopic OSCC model, ISG15-expressing tumors exhibited accelerated growth and recruited more tumor-reactive CD8+ T cells; however, these cells were functionally impaired. Moreover, PD-1 blockade treatment significantly slowed tumor progression and restored T-cell function in ISG15-expressing tumors. Together, our findings reveal that chronic ISG15 exposure promotes CD8+ T-cell dysfunction, but these cells remain responsive to PD-1 blockade. Furthermore, this study identifies ISG15 as a potential biomarker for identifying patients who are likely to benefit from PD-1 blockade therapy.

27 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AYAmir Yousif
Amir Yousif
ASAbbey A. Saadey
Abbey A. Saadey
ALAva Lowin
Ava Lowin
AYAsmaa M. Yousif
Asmaa M. Yousif
ASAnkita Saini
Ankita Saini
HGHazem E. Ghoneim
Hazem E. Ghoneim
Epigenetic scarring of terminally dysfunctional CD8 T cells hinders long-term protection and response to immune checkpoint blockade during chronic infections and cancer. We developed a faithful in vitro model for CD8 T cell terminal dysfunction as a platform to advance T cell immunotherapy. Using TCR-transgenic CD8 T cells, we found that 1-week peptide stimulation, mimicking conditions in previous models, failed to induce a stable exhaustion program in CD8 T cells. In contrast, prolonged stimulation for 2-3 weeks induced T cell dysfunction but triggered activation-induced cell death, precluding long-term investigation of exhaustion programs. To better mimic in vivo exhaustion, we provided post-effector, chronic TGFβ1 signals, enabling survival of chronically stimulated CD8 T cells for over 3 weeks. These conditions induced a stable state of terminal dysfunction (T Dysf ), marked by a stable loss of effector, cytotoxicity, and memory programs, along with mitochondrial stress and impaired protein translation. Importantly, transcriptomic and epigenetic analyses confirmed the development of terminal exhaustion-specific signatures in T Dysf cells. Adoptive transfer of T Dysf cells revealed their inability to recall effector functions or proliferate after acute LCMV rechallenge. This novel tractable model system enables investigation of molecular pathways driving T cell terminal dysfunction and discovery of new therapeutic targets for cancer or chronic infections.

3 November 2025
Verified
Other
Open access
YCYu-Lin Chen
Yu-Lin Chen
AYAmir Yousif
Amir Yousif
CCChung-Hsing Chen
Chung-Hsing Chen
ALAva Lowin
Ava Lowin
ASAbbey A. Saadey
Abbey A. Saadey
HGHazem E. Ghoneim
Hazem E. Ghoneim
Suppl. Fig S2: Chronic exposure of ISG15 impairs human CD8+ T cell activation.

3 November 2025
Verified
Other
Open access
PDF file
YCYu-Lin Chen
Yu-Lin Chen
AYAmir Yousif
Amir Yousif
CCChung-Hsing Chen
Chung-Hsing Chen
ALAva Lowin
Ava Lowin
ASAbbey A. Saadey
Abbey A. Saadey
HGHazem E. Ghoneim
Hazem E. Ghoneim
List of Cytokines and Reagents for Macrophage induction.

3 November 2025
Verified
Other
Open access
YCYu-Lin Chen
Yu-Lin Chen
AYAmir Yousif
Amir Yousif
CCChung-Hsing Chen
Chung-Hsing Chen
ALAva Lowin
Ava Lowin
ASAbbey A. Saadey
Abbey A. Saadey
HGHazem E. Ghoneim
Hazem E. Ghoneim
Suppl. Fig S6:Characterization of free and conjugated Isg15 in Isg15-overexpressing tumor cells and their cell proliferation capacity.

3 November 2025
Verified
Other
Open access
YCYu-Lin Chen
Yu-Lin Chen
AYAmir Yousif
Amir Yousif
CCChung-Hsing Chen
Chung-Hsing Chen
ALAva Lowin
Ava Lowin
ASAbbey A. Saadey
Abbey A. Saadey
HGHazem E. Ghoneim
Hazem E. Ghoneim
Suppl. Fig S1: List of Western Blot antibodies, Flow Cytometry antibodies, and primers used in the study.